<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626270</url>
  </required_header>
  <id_info>
    <org_study_id>R-FFS-OTC</org_study_id>
    <nct_id>NCT05626270</nct_id>
  </id_info>
  <brief_title>Human Factors Testing for OTC Use of the Erchonia® LunulaLaser</brief_title>
  <official_title>Human Factors Validation Testing for Over-the-Counter Use of the Erchonia® LunulaLaser™ OTC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erchonia Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erchonia Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human factors validation testing to assess the intended user's ability to correctly, safely,&#xD;
      and effectively set-up, activate and operate the LunulaLaser™ OTC, to administer a treatment&#xD;
      to a suitably qualified client, and to understand the information contained in the Erchonia&#xD;
      LunulaLaser™ OTC Installation and Proper Use Reference Guide and box labeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an uncontrolled simulated-use human factors validation testing design to assess&#xD;
      the intended user's ability to correctly, safely, and effectively set-up, activate and&#xD;
      operate the LunulaLaser™ OTC, to administer a treatment to a suitably qualified client, and&#xD;
      to understand the information contained in the Erchonia LunulaLaser™ OTC Installation and&#xD;
      Proper Use Reference Guide and box labeling.&#xD;
&#xD;
      The study design is comprehensive in scope and conducted in a manner such that the results&#xD;
      will be able to be generalized to the actual intended user and client population under&#xD;
      intended conditions of actual use and be adequately sensitive to capture use errors arising&#xD;
      from either the user interface design and/or the instructional and informative materials.&#xD;
      Study data will be collected in a manner that will facilitate analysis of the root causes of&#xD;
      use errors or problems during the testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Actual">December 23, 2022</completion_date>
  <primary_completion_date type="Actual">December 23, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Human Factors</measure>
    <time_frame>Each study session was completed on a single day, for up to 120 minutes</time_frame>
    <description>A subject user in this study will be considered as either a study 'pass' or a study 'fail,' defined as follows:&#xD;
Study Pass: A subject user who satisfactorily completes both the device setup and treatment procedure will be determined a Study Pass.&#xD;
Study Fail: A subject user who does not satisfactorily complete either one or both of device setup and/or treatment procedure will be determined a Study Fail.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>LunulaLaser OTC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LunulaLaser OTC</intervention_name>
    <description>The LunulaLaser™ OTC is a nonthermal and non-invasive procedure designed to restore the growth of clear, healthy nails in clients with onychomycosis.</description>
    <arm_group_label>LunulaLaser OTC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Currently employed at a nail salon, beauty salon and/or spa, fitness and wellness spa,&#xD;
             or the like.&#xD;
&#xD;
          -  In possession of qualification(s), current licensure(s), certification(s), and/or&#xD;
             accreditation(s), as applicable, to perform their designated tasks at their place of&#xD;
             employment, e.g., cosmetology degree, nail technician, esthetician, massage therapist&#xD;
             etc.&#xD;
&#xD;
          -  Voluntarily signed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erchonia Corporation</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>November 15, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>December 30, 2022</last_update_submitted>
  <last_update_submitted_qc>December 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

